Atlas Trials

An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)

Clinical trial NCT01110993 · COMPLETED

Trial details

NCT number
NCT01110993
Sponsor
Merck KGaA, Darmstadt, Germany
Status
COMPLETED
Study type
OBSERVATIONAL
Multiple Sclerosis, Relapsing-Remitting
Start date
2010-11-01
Primary completion
2013-09-01
Enrollment
65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.